

Stuart K Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6709767/publications.pdf>

Version: 2024-02-01

149
papers

6,987
citations

94415

37
h-index

60616

81
g-index

151
all docs

151
docs citations

151
times ranked

8639
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Digestive Diseases and Sciences, 2023, 68, 291-303.	2.3	2
2	Improved survival of cirrhotic patients with infections in Australian and New Zealand <scp>ICUs</scp> between 2005 and 2017. Liver International, 2023, 43, 49-59.	3.9	2
3	Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective populationâ€based study. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 395-403.	2.8	10
4	A multiâ€site, nurseâ€coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Liver International, 2022, 42, 522-531.	3.9	4
5	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 2022, 20, 2296-2306.e6.	4.4	35
6	Impact of a Mediterranean diet on hepatic and metabolic outcomes in <scp>nonâ€alcoholic</scp> fatty liver disease: The <scp>MEDINA</scp> randomised controlled trial. Liver International, 2022, 42, 1308-1322.	3.9	20
7	Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET. Journal of Nuclear Medicine, 2022, 63, 1899-1905.	5.0	2
8	Liver injury after SARSâ€CoVâ€2 vaccination: Features of immuneâ€mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology, 2022, 76, 1576-1586.	7.3	58
9	Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study. Hepatology International, 2022, 16, 1094-1104.	4.2	2
10	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clinical Infectious Diseases, 2021, 73, e3288-e3295.	5.8	21
11	Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1210-1218.	2.4	19
12	Towards real-time finite-strain anisotropic thermo-visco-elastodynamic analysis of soft tissues for thermal ablative therapy. Computer Methods and Programs in Biomedicine, 2021, 198, 105789.	4.7	10
13	Comparison of 48â€week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network metaâ€analysis. Journal of Viral Hepatitis, 2021, 28, 40-50.	2.0	9
14	In support of communityâ€based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care. Journal of Viral Hepatitis, 2021, 28, 217-218.	2.0	0
15	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Medical Journal of Australia, 2021, 214, 475-483.	1.7	36
16	Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. CardioVascular and Interventional Radiology, 2021, 44, 247-253.	2.0	14
17	Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia. Internal Medicine Journal, 2021, 51, 181-188.	0.8	5
18	Hepatitis C treatment in a coâ€located mental health and alcohol and drug service using a nurseâ€led model of care. Journal of Viral Hepatitis, 2021, 28, 771-778.	2.0	19

#	ARTICLE	IF	CITATIONS
19	Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 642432.	3.5	13
20	Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 942-947.	1.5	9
21	Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. <i>Medical Journal of Australia</i> , 2021, 215, 77-82.	1.7	13
22	Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. <i>Journal of Hepatology</i> , 2021, 75, 1249-1250.	3.7	51
23	Artificial Intelligence in Hepatology: A Narrative Review. <i>Seminars in Liver Disease</i> , 2021, 41, 551-556.	3.6	0
24	Drug-induced liver injury caused by herbal and dietary supplements: where to next?. <i>Medical Journal of Australia</i> , 2021, 215, 259-260.	1.7	0
25	Letter: the diagnostic and prognostic significance of liver histology in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 862-863.	3.7	2
26	Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 524-535.	3.7	57
27	Letter in response: Psychiatrists can treat hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1765-1766.	2.0	0
28	Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1737-1749.	7.3	27
29	Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study. <i>Liver International</i> , 2021, 41, 2934-2943.	3.9	2
30	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
31	Australian recommendations for the management of hepatocellular carcinoma. <i>Medical Journal of Australia</i> , 2021, 215, 334.	1.7	1
32	Controversies in the Management of Hepatitis B. <i>Clinics in Liver Disease</i> , 2021, 25, 785-803.	2.1	4
33	Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis. <i>Scientific Reports</i> , 2021, 11, 20954.	3.3	1
34	A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 889-895.	3.4	6
35	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1900-1906.	5.8	61
36	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 673-679.	2.8	10

#	ARTICLE	IF	CITATIONS
37	An Unusual Cause of Lower Gastrointestinal Bleeding. <i>Gastroenterology</i> , 2020, 158, 834-835.	1.3	1
38	Nonalcoholic fatty liver disease burden: Australia, 2019–2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1628-1635.	2.8	68
39	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	1.5	5
40	Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. <i>BMC Cancer</i> , 2020, 20, 483.	2.6	5
41	Embolisation of Parastomal Varices Using Balloon-Occluded Retrograde Transvenous Obliteration (BRTO). <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1246-1248.	2.0	1
42	Fast computation of desired thermal dose: Application to focused ultrasound-induced lesion planning. <i>Numerical Heat Transfer; Part A: Applications</i> , 2020, 77, 666-682.	2.1	5
43	Survival of patients with ruptured and non-ruptured hepatocellular carcinoma. <i>Medical Journal of Australia</i> , 2020, 212, 277-278.	1.7	2
44	Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 5-15.	2.8	1
45	Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review. <i>Nutrition Reviews</i> , 2019, 77, 765-786.	5.8	11
46	Letter: elderly AIH patients-an important subgroup. Authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 615-615.	3.7	0
47	Are liver transplant centres critical for the critically ill patient with cirrhosis?. <i>Journal of Hepatology</i> , 2019, 71, 637-638.	3.7	0
48	Turmeric Induced Liver Injury: A Report of Two Cases. <i>Case Reports in Hepatology</i> , 2019, 2019, 1-4.	0.7	35
49	Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1450-1451.	3.7	0
50	Reply to “Crashing NASH in Patients Listed for Bariatric Surgery”. <i>Obesity Surgery</i> , 2019, 29, 640-641.	2.1	0
51	Gastric adenocarcinoma causing biliary obstruction without ductal dilatation: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 72.	0.8	0
52	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	3.7	21
53	Declining Mortality of Cirrhotic Variceal Bleeding Requiring Admission to Intensive Care. <i>Critical Care Medicine</i> , 2019, 47, 1317-1323.	0.9	10
54	Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. <i>Obesity Surgery</i> , 2019, 29, 99-108.	2.1	24

#	ARTICLE	IF	CITATIONS
55	RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2019, 156, 1217.	1.3	3
56	Long-term outcomes of primary sclerosing cholangitis: an Australian non-transplant tertiary hospital perspective. <i>Internal Medicine Journal</i> , 2019, 49, 323-327.	0.8	6
57	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. <i>International Journal of Obesity</i> , 2018, 42, 1900-1911.	3.4	22
58	Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. <i>Advances in Nutrition</i> , 2018, 9, 30-40.	6.4	68
59	Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. <i>Journal of Hepatology</i> , 2018, 69, 575-583.	3.7	27
60	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	4.4	39
61	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 259-267.	3.7	41
62	Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (<sc>MELD</sc> ≥ 15). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 401-411.	3.7	18
63	Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. <i>Obesity Reviews</i> , 2018, 19, 281-294.	6.5	22
64	Efficacy and safety of 12 weeks of elbasvir±Alograzoprevir± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The CASCADE study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 457-464.	2.0	24
65	Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity. <i>Obesity Surgery</i> , 2018, 28, 427-436.	2.1	7
66	IDDF2018-ABS-0113...The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
67	IDDF2018-ABS-0114...SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naïve patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies. , 2018, , .		1
68	Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1368-1375.	1.5	14
69	Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. <i>Medical Journal of Australia</i> , 2018, 209, 348-354.	1.7	43
70	Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. <i>Trials</i> , 2018, 19, 383.	1.6	7
71	Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence. <i>Internal Medicine Journal</i> , 2018, 48, 1369-1376.	0.8	8
72	Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methods. <i>BMC Public Health</i> , 2018, 18, 670.	2.9	17

#	ARTICLE	IF	CITATIONS
73	Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 18.	0.8	8
74	Ultrasound-based liver tracking utilizing a hybrid template/optical flow approach. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2018, 13, 1605-1615.	2.8	28
75	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. <i>Obesity Surgery</i> , 2017, 27, 115-125.	2.1	30
76	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
77	Train-the-trainer education and colonoscopy quality indicators: where to now?. <i>Gut</i> , 2017, 66, 1533-1534.	12.1	1
78	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	1.3	215
79	Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 982-989.	2.0	17
80	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 936-943.	2.0	48
81	Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed <sc>LAM</sc>/<sc>ADV</sc> therapy. <i>Liver International</i> , 2017, 37, 827-835.	3.9	13
82	Author Reply—Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2017, 27, 1060-1060.	2.1	0
83	Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. <i>Journal of Medical Economics</i> , 2017, 20, 72-81.	2.1	2
84	Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2017, 27, 1533-1542.	2.1	29
85	Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct-acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1912-1912.	2.8	2
86	Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. <i>Journal of Hepatology</i> , 2017, 67, 1185-1193.	3.7	31
87	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	8.1	22
88	A prospective comparison of cold snare polypectomy using traditional or dedicated cold snares for the resection of small sessile colorectal polyps. <i>Endoscopy International Open</i> , 2017, 05, E1062-E1068.	1.8	26
89	Salvage Therapies for Autoimmune Hepatitis: A Critical Review. <i>Seminars in Liver Disease</i> , 2017, 37, 343-362.	3.6	10
90	The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 867-878.	1.6	11

#	ARTICLE	IF	CITATIONS
91	Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices. Liver International, 2016, 36, 240-245.	3.9	71
92	Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology, 2016, 63, 1205-1212.	7.3	51
93	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver International, 2016, 36, 954-962.	3.9	14
94	Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1276-1292.	3.7	124
95	Supersonic Shear Imaging and Transient Elastography in Obesity. Clinical Gastroenterology and Hepatology, 2016, 14, 484.	4.4	1
96	Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scandinavian Journal of Gastroenterology, 2016, 51, 979-985.	1.5	14
97	A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. SpringerPlus, 2016, 5, 1365.	1.2	8
98	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clinical Infectious Diseases, 2016, 63, 1042-1048.	5.8	56
99	A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol. BMC Gastroenterology, 2016, 16, 14.	2.0	66
100	Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease. International Journal of Cardiovascular Imaging, 2016, 32, 629-636.	1.5	11
101	High-dose vitamin D supplementation and liver histology in NASH: Table 1. Gut, 2016, 65, 717.2-718.	12.1	42
102	The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS ONE, 2015, 10, e0142770.	2.5	49
103	HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths. Medical Journal of Australia, 2015, 202, 479-479.	1.7	4
104	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	27.0	740
105	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1282-1291.	3.2	10
106	Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scandinavian Journal of Gastroenterology, 2015, 50, 567-576.	1.5	29
107	Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. Drugs, 2015, 75, 823-834.	10.9	14
108	Relationship between vitamin D status and response to hepatitis C virus therapy. Hepatology, 2015, 62, 1642-1643.	7.3	2

#	ARTICLE	IF	CITATIONS
109	Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C". Journal of Hepatology, 2015, 63, 531-532.	3.7	0
110	Association Between Reduced Plasma 25-Hydroxyvitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 813-814.	4.4	1
111	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.	2.5	5
112	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1458-1462.	2.8	4
113	Distribution of interferon lambda3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 179-184.	2.8	14
114	Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. Journal of Hepatology, 2014, 61, 1247-1252.	3.7	36
115	ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology, 2014, 59, 2152-2160.	7.3	25
116	Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case-control study. Scandinavian Journal of Gastroenterology, 2014, 49, 1230-1236.	1.5	21
117	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Hepatology, 2014, 60, 676-677.	3.7	2
118	Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 2013, 58, 467-472.	3.7	71
119	Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver International, 2013, 33, 698-705.	3.9	46
120	A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scandinavian Journal of Gastroenterology, 2012, 47, 836-841.	1.5	35
121	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 2012, 17, 849-854.	1.0	2
122	Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety, 2012, 11, 901-909.	2.4	4
123	D-livering the message: The importance of vitamin D status in chronic liver disease. Journal of Hepatology, 2012, 57, 897-909.	3.7	187
124	Treatment with Interferon and Ribavirin. , 2012, , 115-130.		0
125	Investigation of the Safety of Irreversible Electroporation in Humans. Journal of Vascular and Interventional Radiology, 2011, 22, 611-621.	0.5	408
126	Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease. Journal of Hepatology, 2011, 55, 536-544.	3.7	22

#	ARTICLE	IF	CITATIONS
127	Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S4015.	0.4	2
128	Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antiviral Therapy, 2011, 16, 173-180.	1.0	1
129	Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology, 2011, 53, 1109-1117.	7.3	37
130	Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology, 2010, 51, 388-397.	7.3	149
131	Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 655-656.	2.8	2
132	Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology, 2010, 53, 616-623.	3.7	42
133	Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. Hepatology, 2009, 50, 1045-1055.	7.3	60
134	Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 2008, 48, 398-406.	7.3	98
135	Effect of Sustained Viral Response on Hepatic Venous Pressure Gradient in Hepatitis C-Related Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 932-937.	4.4	121
136	Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: Change in epidemiology and clinical presentation. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 191-196.	2.8	26
137	The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver International, 2007, 27, 1402-1408.	3.9	44
138	Effects of Silybum marianum serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 275-280.	2.8	80
139	Re: Impact of screening on survival for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1356-1356.	2.8	0
140	Genomics of Hepatitis B and C Infections: Diagnostic and Therapeutic Applications of Microarray Profiling. Antiviral Therapy, 2006, 11, 541-552.	1.0	8
141	Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 825-832.	2.8	11
142	Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 873-881.	2.8	55
143	Gastroesophageal Reflux (Symptomatic and Silent): A Potentially Significant Problem in Patients With Cystic Fibrosis Before and After Lung Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1522-1529.	0.6	126
144	Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. Journal of Clinical Virology, 2004, 31, 53-57.	3.1	27

#	ARTICLE	IF	CITATIONS
145	Assessment of Long-Term Outcomes of Community-Acquired Hepatitis C Infection in a Cohort With Sera Stored From 1971 to 1975. Hepatology, 2000, 32, 582-587.	7.3	172
146	Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Medical Journal of Australia, 2000, 173, 403-405.	1.7	71
147	Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology, 1996, 110, 848-857.	1.3	287
148	Cholangiocytes express the aquaporin CHIP and transport water via a channel-mediated mechanism.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 13009-13013.	7.1	115
149	Regulation of bicarbonate-dependent ductular bile secretion assessed by luminal micropuncture of isolated rodent intrahepatic bile ducts.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9080-9084.	7.1	71